Floatz logo

CARTIA

Thrombosis

Bristol-Myers SquibbSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Thrombosis cohort.

Asset / SponsorPhaseRating
Rivaroxaban
Shanghai Zhongshan Hospital
Phase 4BBB
Acetylsalicylic Acid
China National Center for Cardiovascular Diseases
Phase 4BBB
Apixaban
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Phase 4BB
Dabigatran
St. Antonius Hospital
Phase 4BB
Tenecteplase
Mahidol University
Phase 4BB

View all 21 →

Same molecule, other indications

CARTIA is also rated in:

abdominal obesity-metabolic syndromeDormant
CC
Indicative ·
46 / 100
View asset →
adenomatous colon polypDormant
CC
Indicative ·
43 / 100
View asset →
prostate neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →